Trastuzumab, Bevacizumab With Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab,
and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric
cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2
agents.